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Summary
Background GNAQ and GNA11 mutant nonuveal melanoma represent a poorly char-
acterized rare subgroup of melanoma with a gene mutation profile similar to
uveal melanoma.
Objectives To characterize these tumours in terms of clinical behaviour and genetic
characteristics.
Methods Patients with nonuveal GNAQ/11 mutated melanoma were identified from
the prospective multicentre tumour tissue registry ADOREG, Tissue Registry in
Melanoma (TRIM) and additional cooperating skin cancer centres. Extensive data
on patient, tumour and treatment characteristics were collected retrospectively.
Targeted sequencing was used to determine tumour mutational burden.
Immunohistochemistry staining was performed for programmed death-ligand 1
and BRCA1-associated protein (BAP)1. Existing whole-exome cutaneous and
uveal melanoma data were analysed for mutation type and burden.
Results We identified 18 patients with metastatic GNAQ/11 mutant nonuveal mela-
noma. Tumours had a lower tumour mutational burden and fewer ultraviolet sig-
nature mutations than cutaneous melanomas. In addition to GNAQ and GNA11
mutations (nine each), six splicing factor 3b subunit 1 (SF3B1), three eukaryotic
translation initiation factor 1A X-linked (EIF1AX) and four BAP1 mutations were
detected. In contrast to uveal melanoma, GNAQ/11 mutant nonuveal melanomas
frequently metastasized lymphatically and concurrent EIF1AX, SF3B1 and BAP1
mutations showed no apparent association with patient prognosis. Objective
response to immunotherapy was poor with only one partial response observed in
10 treated patients (10%).
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Conclusions Our findings suggest that GNAQ/11 mutant nonuveal melanomas are a
subtype of melanoma that is both clinically and genetically distinct from cuta-
neous and uveal melanoma. As they respond poorly to available treatment regi-
mens, novel effective therapeutic approaches for affected patients are urgently
needed.
What is already known about this topic?
• The rare occurrence of GNAQ/11 mutations in nonuveal melanoma has been docu-
mented.
• GNAQ/11 mutant nonuveal melanomas also harbour genetic alterations in EIF1AX,
SF3B1 and BAP1 that are of prognostic relevance in uveal melanoma.
What does this study add?
• GNAQ/11 mutant nonuveal melanomas show metastatic spread reminiscent of cuta-
neous melanoma, but not uveal melanoma.
• GNAQ/11 mutant nonuveal melanomas have a low tumour mutational burden that
is higher than uveal melanoma, but lower than cutaneous melanoma.
What is the translational message?
• Primary GNAQ/11 mutant nonuveal melanomas are a subtype of melanoma that is
clinically and genetically distinct from both cutaneous and uveal melanoma.
• As metastatic GNAQ/11 mutant nonuveal melanomas respond poorly to available
systemic therapies, including immune checkpoint inhibition, novel therapeutic
approaches for these tumours are urgently needed.
The discovery of somatic mutations in melanoma has led to a
better understanding of melanoma pathogenesis and to the
development of drugs targeting these mutations [i.e. v-raf
murine sarcoma viral oncogene homolog B (BRAF) inhibi-
tors], which constitute a major breakthrough in the treatment
of patients with cutaneous melanoma. Most melanomas are
derived from melanocytes located within the cutaneous epi-
dermis, but they can also arise from pigmented cells of the
cutaneous dermis, uvea and iris, mucosal membranes and lep-
tomeninges.1 Epidemiological and molecular genetic data sug-
gest different mechanisms of melanoma genesis. Intermittent
and chronic cumulative sun exposure is a major factor for
many but not all melanoma subtypes.2 While most sun-
exposed cutaneous melanomas harbour oncogenic mutations
in the mitogen-activated protein kinase (MAPK) signalling
pathway [primarily activating mutations of BRAF (40%) and
neuroblastoma rat sarcoma viral oncogene homolog (NRAS)
(20%)],3 these mutations are far less frequent in tumours aris-
ing in acral or mucosal melanoma and do not occur in uveal
melanoma.4
In uveal melanoma, approximately 80% of somatic muta-
tions affect GNAQ and GNA11.5–7 GNAQ and GNA11 code for
members of the Gaq class of G-protein a subunits (Gaq and
Ga11, respectively), which are involved in signalling via G-
protein-coupled receptors. The mutations occur in the rat
sarcoma viral oncogene (RAS)-like domain of the protein,
leading to a constitutively activated GaQ/11 protein that
essentially converts the GaQ/11 protein into an activated
oncogene product.8 Activated GNAQ and GNA11 (GNAQ/11)
mediates downstream stimulation of the MAPK pathway via
phospholipase C (PLCb) and protein kinase C (PKC) and of
the phosphotidylinositol-3 kinase (PI3K)/protein kinase B
(Akt)/mechanistic target of rapamycin and the yes-associated
protein pathways.9 All three signalling pathways are assumed
to contribute to tumour growth and proliferation.
Apart from the mutational pattern, uveal melanoma also
demonstrates a distinct biological behaviour regarding meta-
static spread and treatment response. Despite excellent rates of
local disease control, nearly 50% of patients will ultimately
succumb to metastatic disease, with the most common meta-
static site being the liver.10 In contrast to cutaneous mela-
noma, treatment response to targeted therapy is poor with
reported response rates of generally less than 10% for MAPK
kinase (MEK), Akt and PKC inhibitors.2,10,11 Immune check-
point inhibition (ICI) using anti-programmed cell death pro-
tein (PD)-1 and/or anti-cytotoxic T-lymphocyte-associated
protein (CTLA)4 antibodies has also been disappointing, with
only individual patients responding to immunotherapy.12–16
The low mutational burden of uveal melanoma, differences
regarding expression of neoantigens between cutaneous and
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uveal melanoma, an immunosuppressive tumour microenvi-
ronment, low immunogenicity and an immune-privileged site
of uveal melanoma have been held responsible for the failure
of immunotherapy.17
GNAQ/11 mutations can also occur in cutaneous melanocy-
tic proliferations. They are frequent in dermal melanocytic
tumours such as blue naevi (83%) and blue naevus-like mela-
noma (50%),8 and less frequent in common cutaneous or
mucosal melanoma.18–20 According to the classic progression
model, benign tumours (naevi) frequently harbour an initial
activating mutation (e.g. a BRAF or GNAQ/11 mutation).
Acquisition of additional genetic alterations is required for
progression to a malignant neoplasm (melanoma).21 In uveal
melanoma, additional mutations are typically found in splicing
factor 3b subunit 1 (SF3B1), eukaryotic translation initiation
factor 1A X-linked (EIF1AX) or BRCA1-associated protein
(BAP)1. Interestingly, they mostly occur in a mutually exclu-
sive manner and have prognostic relevance.21 While inactivat-
ing BAP1 mutations are associated with a poor prognosis,22
SF3B1 and EIF1AX mutated uveal melanomas show a more
favourable course of disease.23,24 Recently, we were able to
demonstrate that SF3B1 and BAP1 alterations are present in
17% and 25% of blue naevus-like melanoma, respectively.21
Johnson et al. additionally described concurrent GNAQ/11 and
SF3B1 or EIF1AX mutations in nonuveal melanoma.25
It is uncertain to what extent the molecular linkage between
GNAQ/11 mutant uveal and nonuveal melanoma also translates
into a biological relationship, in particular regarding the fre-
quency and pattern of metastatic spread and the poor response
to immunotherapy. We therefore identified patients with
nonuveal melanoma who had metastatic disease and known
GNAQ/11 mutations, assessing course of disease, additional
somatic mutations, tumour mutational burden (TMB) and
mutation signature in order to investigate whether experiences
with uveal melanoma can be transferred to nonuveal mela-
noma with GNAQ/11 mutations.
Patients and methods
Patient selection
The database of the prospective multicentre translational study
Tissue Registry in Melanoma (TRIM) was screened for nonu-
veal melanoma with known activating hotspot mutations of
GNAQ and GNA11. The TRIM study has previously been
described elsewhere.26 In brief, formalin-fixed paraffin-
embedded (FFPE) tumour tissues were prospectively collected
and analysed within the framework of the skin cancer registry
ADOREG (German Dermatologic Cooperative Oncology
Group). The TRIM study was approved by the ethics commit-
tee of the University of Duisburg-Essen (15-6566-BO). Of
1060 patients registered in TRIM on 15 September 2018, 15
patients had GNAQ/11 mutations.
Additional patients not captured in the registry (n = 9) were
identified retrospectively from the dermatology departments
of the university hospitals of Cologne (n = 3), Essen (n = 2),
Heidelberg (n = 2), T€ubingen (n = 1) and W€urzburg (n = 1).
For these patients, samples were collected during routine care
and confirmatory GNAQ/11 mutation analysis was performed
using next-generation sequencing as described below. Histo-
logical evaluation was carried out by the local board-certified
pathologists or dermatopathologists. Five cases (cases 2, 3, 4,
10 and 15) were described in a previous study.21 Clinical data
(including sex and age at diagnosis) in addition to tumour-
specific information (localization, histological type, tumour
thickness, ulceration, regression, sentinel node biopsy, stage at
initial diagnosis, metastatic progress, type, duration and
response to systemic treatment) was required for each patient
and information was obtained from the local institution. The
study was performed and approved in accordance with the
guidelines of the ethics committee of the University of Duis-
burg-Essen (18-8110-BO).
DNA isolation
DNA was isolated from FFPE tumour tissue cut into 10-lm
thick sections. After deparaffinization, sections were manually
macrodissected according to standard procedures. Genomic
DNA was isolated using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s instructions.
Targeted sequencing and genetic analysis
All samples were sequenced applying a 10-gene custom ampli-
con-based panel as previously described,21 covering known
recurrent mutations in uveal and cutaneous melanoma [GNAQ,
GNA11, phospholipase C-b4 (PLCB4), cysteinyl leukotriene
receptor 2 (CYSLTR2), EIF1AX, SF3B1, BAP1, BRAF, NRAS and
tyrosine-protein kinase (KIT)]. A 130-gene panel27 was
applied to determine TMB in eight samples where sufficient
high-quality DNA for analysis was available (cases 2, 5, 7, 8,
10, 11, 12 and 18). Existing whole-exome data of cutaneous
and uveal melanoma samples from The Cancer Genome Atlas
(TCGA) were analysed for mutation type and mutation bur-
den.28,29 A detailed description of all methods applied for
sequencing and genetic data in addition to the statistical analy-
sis performed is listed in the supplemental material and meth-
ods (File S1; see Supporting Information).
BRCA1-associated protein 1 programmed death-ligand 1
immunohistochemistry
BAP1 immunohistochemistry (IHC) was performed, applying
a rabbit polyclonal antibody recognizing amino acids 430–
729 of the BAP1 protein (clone C-4, Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) as previously reported.30 Nuclear stain-
ing was assessed for positivity. Programmed death-ligand 1
(PD-L1) expression was assessed in FFPE tumour specimens,
with the use of a rabbit monoclonal antihuman PD-L1 anti-
body (clone 28-8) and an analytically validated automated
immunohistochemical assay (PD-L1 IHC 28-8 pharmDx for
Autostainer Link 48; Dako, Glostrup, Denmark).31 PD-L1
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positivity was defined as at least 5% of living tumour cells
showing membranous staining of any intensity in a section
containing at least 100 evaluable tumour cells.
Results
Sample cohort
Of the 24 patients in whom a GNAQ/11 mutation was identi-
fied, six were excluded for further analysis as they either had
ocular melanoma or nonmetastatic disease (two uveal mela-
noma, one ciliary body melanoma, one nonmetastatic disease)
or because the GNAQ/11 mutation could not be confirmed
(two cases). In all other cases, a primary uveal melanoma was
excluded by ophthalmological assessment and/or imaging by
computed tomography/magnetic resonance imaging. The rate
of GNAQ/11 mutation in nonuveal melanoma in TRIM was 11
of 1039 patients (11%). The median age of the remaining 18
patients was 52 years (range 13–75) and 67% were male
(Tables 1 and 2). In six patients, the tumour was diagnosed
as melanoma of unknown primary (MUP). In patients with
known primary, only five were clearly identified as melanoma
on the first histopathology report. In two cases, the
histopathologist could not initially differentiate between a pri-
mary melanoma and a benign melanocytic proliferation, and
in four cases between a primary melanoma and a subcuta-
neous metastasis (Table 3). In eight patients, the primary was
located in regions typical for blue naevus [scalp/head (n = 5)
(Figure 1), buttocks/sacrococcygeal region (n = 2), scrotal (n
= 1)]. In patients with known primary, median tumour thick-
ness was 75 mm (range 085–89). Only two primaries were
ulcerated.
Of the six patients diagnosed with MUP, three had macro-
scopic axillary lymph node metastases (patient 1, 10 and 14)
and one had retroperitoneal lymph node metastases (patient
11) at initial diagnosis. In patients 12 and 17, it could not be
determined whether the patients had primary cerebral mela-
noma or MUP with cerebral metastases.
Seven patients (39%) presented with a locoregional metasta-
sis at initial diagnosis and five patients (28%) presented with
distant metastasis. In patients without metastasis at initial diag-
nosis, median time to stage IV disease was 49 months (range
5–132). Four patients have not yet progressed to stage IV. At
a median follow-up time of 48 months (range 3–201), 11
patients died as a result of melanoma.
Distribution of mutations and immunohistochemistry for
BRCA1-associated protein 1 and programmed death-
ligand 1
In 13 patients, a metastasis was used for targeted amplicon
sequencing and IHC, and the primary was assessed in five
patients. GNA11 and GNAQ were detected with equal frequency
(Figure 2). Of the nine GNA11 mutations, eight affected
c.626A>T (pQ209L) and one affected c.627G>C (pQ209H).
Of the nine GNAQ mutations, seven affected c.626A>T
(pQ209L), one affected c.627A>T (pQ209H) and one affected
c.626A>G (pQ209R). Additional mutations were found in 12
patients (67%). Six patients had SF3B1 mutations (three
c.1873C>T1 pR625C, three c.1874G>A pR625H), four
patients had BAP1 mutations (c.182_186delAGGTC pK61fs,
c.757C>T pQ253*, c.1957G>T pE653*, c.1873C>T pP175F)
and three patients had EIF1AX mutations (c.25G>C G9R,
c.6delC pK3fs, c.10A>G pN4D). The patient with the vaginal
melanoma harboured a GNA11 c.627G>C pQ209H and a KIT
Table 1 Summary of patient and tumour characteristics of the cohort
of patients with nonuveal metastatic melanoma who had GNAQ/11
mutation
Median age at diagnosis, years (range) 515 (13–75)
Median follow-up, months (range) 475 (3–201)
Sex
Male 12 (67)
Female 6 (33)
Vital status
Dead 11 (61)
Melanoma-specific death 11 (100)
Stage at diagnosisa,b
Min. IA 1 (6)
IB 1 (6)
IIB 4 (22)
Min. IIIA 1 (6)
IIIB 2 (11)
IIIC 4 (22)
IV 5 (28)
Tumour thickness
Not available 4 (22)
MUP 6 (33)
Median, mm (range) 75 (085–14)
Location of primary
MUP 6 (33)
Head/neck 5 (28)
Upper extremity 1 (6)
Trunkc 5 (28)
Lower extremity 0
Vagina 1 (6)
Sentinel lymph node biopsy
Done 3 (17)
Positive 3 (1000)
Location of first metastasis
Sentinel lymph node 3 (17)
Macroscopic lymph nodes 4 (22)
Cutaneous/subcutanoeus 3 (17)
Brain 2 (11)
Lung 2 (11)
Cardiac 1 (6)
Urethra 1 (6)
Multitopic 2 (11)
Data are presented as n (%) unless otherwise stated. MUP, mela-
noma of unknown primary. aClassified according to American
Joint Committee on Cancer staging system, 8th edition. bFour
patients progressed to a maximum stage III, five had stage IV
without prior stage III disease, all other patients progressed to
stage IV (one patient only had retroperitoneal lymph node
metastases). cTwo located on lower back/buttocks, one wide-
spread on scrotum.
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mutation (c.1924A>G pK642E). One patient with a GNAQ
c.626A>G pQ209R mutation had a concurrent NRAS c.181C>A
(pQ61K) mutation.
Loss of BAP1 protein expression could be confirmed by IHC
in all four patients demonstrating a BAP1 mutation. Of the 10
patients assessed for PD-L1 status, four showed positive stain-
ing and one was not evaluable.
Systemic therapy and response to treatment
A systemic first-line therapy for stage IV disease was given in
13 patients (Table 2). Most regimens (n = 10) were ICI-based;
four of these were combination therapies (three anti-PD-1
antibody plus anti-CTLA4 antibody, one anti-PD-1 antibody
plus epacadostat), four were anti-PD-1 antibody monothera-
pies and two were anti-CTLA4 antibody monotherapies. The
best treatment response to ICI was progressive disease in seven
patients, only one patient showed partial response (PR) (pem-
brolizumab plus epacadostat) and one exhibited stable disease
(ipilimumab plus nivolumab). (Poly)chemotherapy treatments
were administered in three patients, one in combination with
nintedanib. One patient showed a complete response to cis-
platin, dacarbazine and vindesine but progressed later. The
other patients had stable disease and progressive disease as
best responses. Second-line treatments were administered in
10 patients, seven of which were ICI treatments. Only two
patients showed PR and a stable disease response to ICI ther-
apy; however, one of these patients showed this response only
in a concomitantly irradiated area. Three patients received
chemotherapy or imatinib (patient with vaginal melanoma
harbouring a KIT mutation), with stable disease as the best
treatment response. Additional treatment lines were given in
seven patients.
Tumour mutational burden and mutation distribution
To compare the mutational load and the amount of ultraviolet
(UV) signature mutations, we assessed the TMB in eight sam-
ples, applying a larger sequencing panel covering 091 mega-
base of DNA. Our samples had lower mutation frequencies
compared with other samples assessed using this panel (Fig-
ure 3a). Hypermutated samples were intentionally chosen for
comparison. For each entity one case was used so that the
comparison did not reflect a media of the single-nucleotide
variant frequently mutated in each entity. To allow a compar-
ison of GNAQ/11 mutated tumours with a large cohort of
other cutaneous melanomas, we assessed publicly available
whole-exome datasets. GNAQ/11 mutated tumours had lower
mutational burden than GNAQ/11 wildtype tumours (P =
002, Wilcoxon test; Figure 3b). When we compared the sub-
stitution types of GNAQ/11 mutated nonuveal melanomas
(within TCGA) with GNAQ/11 wildtype cutaneous and uveal
melanomas, an intermediate profile was identified, demon-
strating fewer C>T alterations (median 707%) than most
cutaneous melanoma samples (85%); however, this was con-
siderably more than in uveal melanoma samples (48%, Fig-
ure 3c).
Discussion
In summary, we analysed a cohort of metastatic GNAQ/11
mutant melanomas that were not of uveal origin. These
tumours are rare32,33 and our data demonstrate that their bio-
logical behaviour is distinct from conventional cutaneous and
uveal melanoma.
The histological evaluation of GNAQ/11 mutant nonuveal
melanomas seems to be challenging. In six tumours from our
cohort the initial diagnosis was uncertain, as differentiation
from benign melanocytic proliferations or subcutaneous
metastasis was difficult. Cutaneous melanoma is mostly epider-
mally derived and histological detection of a dermal malignant
melanocytic proliferation without epidermal involvement gen-
erally represents a cutaneous metastasis. However, in GNAQ/11
mutant cutaneous melanomas the tumour arises in the dermis.
Therefore, we believe that this data suggests that cases of non-
benign dermal melanocytic proliferations should be sequenced
to exclude a primary GNAQ/11 mutant cutaneous tumour.
Whenever a GNAQ/11 mutation is detected, clinical analysis
and/or imaging should be performed to exclude uveal mela-
noma, as most GNAQ/11 mutant melanomas arise in the uveal
region.
Interestingly, one-third of patients reported in this study
were diagnosed with MUP. This rate is remarkably higher than
the < 20% rate of MUP diagnosed among all patients with
melanoma who present with regional or distant metastasis.34
In two of the cases diagnosed as MUP, patients were reported
Figure 1 Blue naevus-like melanoma on the scalp of a 22-year old
male patient (case 8). Breslow index 14 mm, no ulceration. The
initial histology report described a lesion compatible with metastasis
of melanoma or a subcutaneous malignant cellular blue naevus. At the
time of initial diagnosis, the tumour had already metastasized to the
skin and liver. The patient received ipilimumab and second-line
treatment with dacarbazine and died approximately 2 years after the
first melanoma diagnosis.
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to have cerebral metastasis as the first tumour localization.
Retrospectively, it is likely that both cases represented a cere-
bral primary rather than a metastasis (case 12 and case 17).
Of the other four MUP cases, three patients had lymph node
metastases and one patient had a polytopic metastasis at first
diagnosis. Primary tumours in blue naevus-like melanoma can
be located deep in the dermis and therefore they may never
be detected, they may be mistaken for a subcutaneous metas-
tasis (case 14) or before being recognized they may have gone
into complete remission (cases 1, 10 and 11) and patients
present with palpable lymph node metastases.
In this cohort of metastatic GNAQ/11 nonuveal melanomas,
most of the GNAQ/11 mutations were the well-recognized
activating Q209L hotspot mutations. Three rarer 209 muta-
tions, a Q209R and two Q209H mutations were also identi-
fied. Interestingly, in two cases the tumours were found to
harbour additional activating mutations in other genes. The
GNA11 Q209H samples also had a KIT K642E mutation and
the GNAQ Q209R mutant sample had a concurrent NRAS Q61K
mutation. This is unusual as mutations in GNAQ/11 and acti-
vating BRAF, RAS or KIT mutations are generally mutually
exclusive.6,35 This could suggest that Q209R or Q209H muta-
tions are less activating, with tumours requiring additional
mutations to promote malignant behaviour. If this proves true,
tumours should potentially be primarily grouped based on the
other present activating mutation (i.e. KIT or NRAS). Larger
cohorts and functional studies will be required to elucidate
this assumption further.
Similar to uveal melanoma,24,29,33 we found GNAQ/11
mutations in cutaneous melanoma to co-occur frequently with
EIF1AX, SF3B1 or BAP1 mutations. The numbers in this study
are of course very low, but a clear association of different
genetic events with prognosis, as observed in uveal melanoma,
was not apparent. Patients with BAP1 alteration tumours were
not found to have an obvious poorer prognosis than patients
with tumours harbouring EIF1AX or SF3B1 mutations. These
data will need to be assessed in larger cohorts (when avail-
able); however, our current data suggest that prognosis of
patients with cutaneous GNAQ/11 mutant melanoma cannot be
reliably predicted based on EIF1AX, SF3B1 or BAP1 status.
The metastatic profile of our cohort draws attention to
another interesting finding of our study. Uveal melanomas
metastasize primarily haematologically to the liver36 and initial
lymph node metastasis, as is frequent in cutaneous melanoma,
generally does not occur. The reason for this metastatic spread
pattern is thought to be the lack of a lymphatic drainage sys-
tem in the uvea. Another possibility is that uveal melanomas
intrinsically metastasize haematologically. In our cohort of
patients with cutaneous GNAQ/11 mutant melanoma, almost
all patients had lymph node metastases and some even had
positive sentinel lymph nodes. This suggests that such genetic
alterations are not associated with a primary haematological
metastasis and despite having a similar genetic signature to
uveal melanoma, GNAQ/11 mutant nonuveal melanomas
metastasize lymphatically and therefore routine clinical analysis
of the draining lymphatic tissue should be performed.
TMB may be associated with poor response to immunother-
apy.37 High TMB has been associated with stronger response
to immunotherapy in most cancers.38 While TMB is high in
cutaneous melanoma, it is notoriously low in uveal mela-
noma.29 In both targeted sequencing of eight tumour samples
from our cohort, and in an analysis of publicly available
sequencing data from GNAQ/11 mutant cutaneous melanoma
in the TCGA cohort (Figure 3), a low TMB was detected.
When examining the TCGA data, the difference in mutation
number compared with conventional cutaneous melanoma
samples was found to be statistically significant. The mutation
profile of samples from our cohort showed fewer UV
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
GNA11
GNAQ
SF3B1
BAP1
EIF1AX
KIT
NRAS
Q209L Q209 H Q209L Q209H Q209R
R625C R625H Q253* E653* P175F
K61fs K3fs N4d G9r K642E
Q61K
Figure 2 Activating mutations identified by targeted next-generation sequencing in 18 patients with metastatic melanoma and GNAQ or GNA11 mutation.
SF3B1, splicing factor 3b subunit 1; BAP1, BRCA1-associated protein; EIF1AX, eukaryotic translation initiation factor 1A X-linked; KIT, tyrosine-protein
kinase; NRAS, neuroblastoma rat sarcoma viral oncogene homolog. Different protein alterations are depicted by assorted colour shades.
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mutations compared with cutaneous melanoma. The explana-
tion for this appears to be straightforward, as GNAQ/11
mutant cutaneous tumours usually arise in the dermis and are
only modestly exposed (if at all) to UVB irradiation, which is
primarily absorbed in the epidermis. However, the TCGA data
analysis did suggest that more mutations with a UV signature
are found in GNAQ/11 mutant cutaneous melanomas than
uveal melanomas.
In recent years, therapeutic options for cutaneous melanoma
have improved dramatically with the use of BRAF and MEK
inhibitors, and impressive therapeutic responses have been
demonstrated by ICI.39–43 However, these therapeutic
advances cannot be transferred to GNAQ/11 mutant uveal mel-
anomas. BRAF/MEK inhibition is not an option in GNAQ/11
mutant tumours. Immunotherapy has demonstrated poor effi-
cacy in uveal melanoma.12,44 The findings of our current
cohort suggest that GNAQ/11 mutant nonuveal melanomas also
respond poorly to immunotherapy. The efficacy of
immunotherapy will need to be further assessed in larger
studies. Considering a lack of other effective therapeutic
approaches, immunotherapy certainly remains a valid thera-
peutic option, potentially even the best option that is currently
available. When novel therapies for uveal melanoma become
available, these might also prove to be valuable for nonuveal
GNAQ/11 mutant melanoma.
Our study has some limitations. The significance of our
findings is limited by the small number of cases owing to the
rarity of GNAQ/11 mutant nonuveal tumours. Validation stud-
ies should be performed using larger cohorts. Furthermore,
the studies were performed on heterogeneous samples, as
both primary tumours and metastases were used, and tissue
samples were derived at different timepoints during the
cutaneous melanoma n = 339 GNAQ/11 mutant
nonuveal melanoma n = 6
uveal melanoma n = 74
So
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Figure 3 (a) Comparison of number of single-nucleotide variant (SNV) calling of eight GNAQ/11 mutant melanoma samples vs. hypermutated
tumours as controls. Tumour mutational burden of our cohort was low compared with other heavily mutated samples. (b) Mutational burden of
The Cancer Genome Atlas (TCGA) melanoma tumours comparing GNAQ/11 mutated vs. wildtype (wt) samples (Wilcoxon test). The sums of
nonsynonymous somatic mutations are shown, which can be assumed to have the potential to create neoantigens. GNAQ/11 mutated tumours have
significantly lower mutational burden than GNAQ/11 wildtype tumours. (c) Comparison of single-nucleotide substitutions for somatic variants in a
cutaneous melanoma cohort (n = 339), GNAQ/11 mutant nonuveal melanoma (n = 6) and a uveal melanoma cohort (n = 74) showed an
intermediate profile of nonuveal GNAQ/11 mutated melanomas demonstrating a lower ultraviolet gene signature (C>T alterations, yellow) than
cutaneous melanoma and a higher ultraviolet gene signature than uveal melanoma. ETMR, embryonal tumours with multilayer rosettes; GBM MID,
glioblastoma multiforme midline; MB SHH CHL AD, methylation class medulloblastoma, subclass sonic hedgehog A (children and adult); SKCM,
skin cutaneous melanoma.
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disease course. Moreover, there was also heterogeneity with
regard to systemic treatments. While these factors could affect
mutational status, they are not likely to have influenced the
genes relevant for this study. PD-L1 expression can vary
between primary and metastatic tissue and can change with
systemic treatment. As it is not a clear marker for response to
therapy in melanoma, we intentionally did not focus on PD-
L1 expression in our study; however, we did report it for the
sake of completeness. The TMB analysis could be performed
in only eight patients owing to the lack of sufficient high-
quality DNA in the remaining samples.
In summary, the clinical data and the mutation profile sug-
gest that GNAQ/11 mutant nonuveal melanomas differ signifi-
cantly from conventional cutaneous melanoma. Despite a
strong genetic relationship, they also differ from uveal mela-
noma by having more UV mutations and a different metastatic
pattern. Similar to uveal melanoma, it appears that patients
with these tumours do not benefit sufficiently from recent
treatment advances in advanced melanoma and require novel
therapeutic approaches.
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